BTIG analyst Sam Eiber initiated coverage of Evolus (EOLS) with a Buy rating and $21 price target Evolus is a performance beauty company that operates in the cash-pay medical aesthetic market, the analyst tells investors in a research note. The firm says the company’s “differentiated go-to-market strategy” as a non-therapeutic, cash-pay company allows it to bypass third-party payer reimbursement dynamics, enabling greater pricing flexibility and the ability to reinvest into provider practices through co-branded marketing initiatives. BTIG sees several paths for Evolus to achieve its goal of at least $700M in revenue and non-GAAP operating income margin of at least 20%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EOLS:
- Evolus’s Jeuveau Growth and Resilience Amid Economic Uncertainties Supports Buy Rating
- Optimistic Outlook for Evolus: Buy Rating Backed by Strategic Positioning and Strong Product Performance
- Evolus’s Strong Market Position and Growth Potential Highlighted by Robust Revenues and Strategic Expansions
- Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty
- Evolus, Inc. Earnings Call Highlights Robust Growth and Profitability
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue